New evolution with longer range and higher capacity
TOULOUSE, 09-Jan-2018 — /EuropaWire/ — Airbus has completed assembly of the first A321neo ACF (Airbus Cabin Flex) at its facilities in Hamburg, Germany. The aircraft, powered by CFM LEAP-1A engines, will undergo ground tests prior to its scheduled first flight in the coming weeks. First delivery of an A321neo ACF to a customer is scheduled for mid-2018.
The A321neo ACF is the latest addition to the successful A320 Family. By applying modifications to the fuselage, the ACF enables more flexible cabin configurations for up to 240 passengers. Compared to the previous A321 variant, the most visible modifications are a new rear section and a modified passenger door configuration, where the door located forward of the wing is removed and new overwing emergency exits in the centre section are introduced. The A321neo ACF is an option today and will become standard for all A321neos around 2020.
The A321neo ACF is the base for a longer range variant known as the A321LR. The A321LR has an increased MTOW (Maximum Take Off Weight) of 97 tonnes and a third underfloor fuel tank allowing airlines to increase its range to 4,000 nautical miles for intercontinental flights. The first delivery of an A321LR is targeted for the fourth quarter of 2018.
The A321 is the largest member of the A320 Family, seating up to 240 passengers, depending on cabin configuration. Incorporating the latest engines, aerodynamic advances and cabin innovations, the A321neo offers a reduction in fuel consumption of at least 15 percent per seat from day one and 20 percent by 2020.
Contact:
Patrick Brunet
Media Relations Manager
+33 5 82 05 96 20
Martina Juergens
Head of Communications
+49 407 437 3220
Source: Airbus
###
(IN BRIEF) Eurex, on April 29, 2024, introduced a new Green Bond Basket within its…
(IN BRIEF) Last Friday, NMB Bank Plc celebrated the listing of its dual-currency sustainability bond,…
(IN BRIEF) CapMan Nordic Infrastructure II fund has reached its final closing at over €375…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the…
(IN BRIEF) Ørsted, a global leader in renewable energy, is divesting its French onshore operations…